Global Emphysema Drug Market By Type (Paraceptal, Pentrilobular and Panlobular), Mechanism of Action Type (Bronchodilators, Beta-agonists, Anticholinergics, Corticosteroids, Phosphodiesterase -4 Inhibitors and Mucolytics), Stages Type (Very Mild or Stage 1: FEV1 is About 80.0% of Normal, Moderate or Stage 2: FEV1 is Between 50.0% and 80.0% of Normal, Severe or Stage 3: FEV1 is Between 30.0% and 50.0% of Normal and Very Severe or Stage 4: FEV1 is Lower Than in Stage 3, or The Same as Stage 3 But With Low Blood Oxygen Levels), Therapy Type (Oxygen Therapy and Protein Therapy), Drug Type (Aclidinium, Formoterol, Salmeterol, Levalbuterol, Ipratropium, Olodaterol, Ffluticasone, Budesonide and Prednisolone), Route of Administration (Oral, Inhaled, Intravenous and Others), Surgery Type (Lung Volume Reduction Surgery and Lung Transplant Surgery), Device Type (Inhalers, Pressurized Metered-Dose Inhalers (MDIS) , Dry-Powder Inhalers (DPIS), Nebulizers and Soft Mist Inhalers), End Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights of Emphysema Drug Market
Data Bridge Market Research analyses that the emphysema drug will exhibit a CAGR of around 6.30% for the forecast period of 2021-2028. Rising concerns regarding patient’s health, high prevalence of smoking, increasing global healthcare expenditure and technological advancements in pharmaceuticals research are the major factors attributable to the growth of emphysema drug market.
Emphysema, also known as obstructive lung disease, involves shortness of breath due to the damaged alveolar sacs which are involved in exchange of gases. Emphysema comes with anxiety, stress, weight loss, excess mucous, shortness of breath, fatigue, reduced appetite and sleep related problems.
Additionally, rising prevalence of emphysema is bolstering the growth of emphysema drug market. Rising collaboration of major key players with the regulatory bodies and research institutes to develop novel treatment options is also fostering the growth of the market.
However, expensive treatment of emphysema will pose a major challenge to the market. Patent expiry of generic drugs will further slowdown the market growth rate.
This emphysema drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on emphysema drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Emphysema Drug Market Scope and Market Size
The emphysema drug market is segmented on the basis of type, mechanism of action type, stages type, therapy type, drug type, route of administration, surgery type, device type and end users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on the type, the emphysema drug market has been segmented into paraceptal, pentrilobular and panlobular.
- Based on the mechanism of action type, the emphysema drug market has been segmented into bronchodilators, beta-agonists, anticholinergics, corticosteroids, phosphodiesterase -4 inhibitors and mucolytics.
- On the basis of stages type, the emphysema drug market is segmented into very mild or stage 1: FEV1 is about 80.0% of normal, moderate or stage 2: FEV1 is between 50.0% and 80.0% of normal, severe or stage 3: FEV1 is between 30.0% and 50.0% of normal and very severe or stage 4: FEV1 is lower than in stage 3, or the same as stage 3 but with low blood oxygen levels.
- On the basis of therapy type, the emphysema drug market is segmented into oxygen therapy and protein therapy.
- On the basis of drug type, the emphysema drug market is segmented into aclidinium, formoterol, salmeterol, levalbuterol, ipratropium, olodaterol, fluticasone, budesonide and prednisolone.
- On the basis of route of administration, the emphysema drug market is segmented into oral, inhaled, intravenous and others.
- On the basis of surgery type, the emphysema drug market is segmented into lung volume reduction surgery and lung transplant surgery.
- On the basis of device type, the market is segmented into inhalers, pressurized metered-dose inhalers (MDIS), dry-powder inhalers (DPIS), nebulizers and soft mist inhalers.
- On the basis of end users, the market is segmented into hospitals, homecare, specialty clinics and others.
Core Emphysema Drug Market Country Level Analysis
The emphysema drug market is analysed and market size insights and trends are provided by country, type, mechanism of action type, stages type, therapy type, drug type, route of administration, surgery type, device type and end users as referenced above.
The countries covered in the emphysema drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the emphysema drug market owing to the prevalence of sophisticated healthcare infrastructure, increased research and development proficiencies by the pharmaceutical companies and rapid adoption of new and better healthcare technologies. Rising prevalence of emphysema is also steering the industry trends in this region. Asia-Pacific on the other hand is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure coupled with rising involvement of regulatory bodies for research and development activities. Rising consumption of smoking and other tobacco products is also fostering market growth in this region.
The country section of the emphysema drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Emphysema drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Emphysema Drug Market Share Analysis
The emphysema drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to core emphysema drug market.
The major players covered in the emphysema drug market report are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company., Astrazeneca, Pfizer Inc., Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, Sanofi, Bayer AG, AbbVie Inc., Allergan, Precigen., Pulmonx Corporation, Halozyme, Inc., mariposa Health, Kamada Pharmaceuticals., Olympus Corporation, Spiration, Inc. and Lifetech Scientific among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-